{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"3"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"3"},{"groupId":"OG010","value":"3"}],"units":"Participants"}],"description":"Number of patients of response-evaluable participants with response (CR/PR) assessed according to Response Evaluation Criteria in Solid Tumors version 1.1 including CR: disappearance of all target and non-target lesions; PR: at least 30% decrease in the sum of the diameters of target lesions","groups":[{"description":"Patients receive 165 mg/m\\^2 crizotinib (oral solution) PO BID on days 1-21, 250 mg/m\\^2 cyclophosphamide IV QD on days 1-5, and topotecan hydrochloride IV QD on days 1-5. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. (closed to accrual 10/3/14)","id":"OG000","title":"Part A Dose Level 1"},{"description":"Patients receive 215 mg/m\\^2 crizotinib (oral solution) PO BID on days 1-21, 250 mg/m\\^2 cyclophosphamide IV QD on days 1-5, and topotecan hydrochloride IV QD on days 1-5. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. (closed to accrual 10/3/14)","id":"OG001","title":"Part A Dose Level 2"},{"description":"Patients receive 165 mg/m\\^2 crizotinib (oral solution) PO BID as in Part A. Patients also receive 1.5 mg/m\\^2 vincristine sulfate IV on day 1, 450 mg/m\\^2 dexrazoxane hydrochloride IV on day 1, and 45 mg/m\\^2 doxorubicin hydrochloride IV over 15 minutes on day 1. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. (closed to accrual 10/3/14)","id":"OG002","title":"Part B Dose Level 1"},{"description":"Patients receive 215 mg/m\\^2 crizotinib (oral solution) PO BID as in Part A. Patients also receive 1.5 mg/m\\^2 vincristine sulfate IV on day 1, 450 mg/m\\^2 dexrazoxane hydrochloride IV on day 1, and 45 mg/m\\^2 doxorubicin hydrochloride IV over 15 minutes on day 1. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. (closed to accrual 10/3/14)","id":"OG003","title":"Part B Dose Level 2"},{"description":"Patients receive 280 mg/m\\^2 crizotinib (oral solution) PO BID as in Part A. Patients also receive 1.5 mg/m\\^2 vincristine sulfate IV on day 1, 450 mg/m\\^2 dexrazoxane hydrochloride IV on day 1, and 45 mg/m\\^2 doxorubicin hydrochloride IV over 15 minutes on day 1. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. (closed to accrual 10/3/14)","id":"OG004","title":"Part B Dose Level 3"},{"description":"Patients receive 165 mg/m\\^2 crizotinib (capsule formulation) PO BID, 250 mg/m\\^2 cyclophosphamide IV QD, and topotecan hydrochloride IV QD as in Part A. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.","id":"OG005","title":"Part C Dose Level 1"},{"description":"Patients receive 215 mg/m\\^2 crizotinib (capsule formulation) PO BID, 250 mg/m\\^2 cyclophosphamide IV QD, and topotecan hydrochloride IV QD as in Part A. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.","id":"OG006","title":"Part C Dose Level 2"},{"description":"Patients receive 280 mg/m\\^2 crizotinib (capsule formulation) PO BID, 250 mg/m\\^2 cyclophosphamide IV QD, and topotecan hydrochloride IV QD as in Part A. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.","id":"OG007","title":"Part C Dose Level 3"},{"description":"Patients receive 165 mg/m\\^2 crizotinib (microsphere formulation) PO BID, 250 mg/m\\^2 cyclophosphamide IV QD, and topotecan hydrochloride IV QD as in Part A. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.","id":"OG008","title":"Part D Dose Level 1"},{"description":"Patients receive 215 mg/m\\^2 crizotinib (microsphere formulation) PO BID, 250 mg/m\\^2 cyclophosphamide IV QD, and topotecan hydrochloride IV QD as in Part A. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.","id":"OG009","title":"Part D Dose Level 2"},{"description":"Patients receive 215 mg/m\\^2 crizotinib (microsphere formulation) PO BID, 250 mg/m\\^2 cyclophosphamide IV QD, and topotecan hydrochloride IV QD as in Part A. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity.","id":"OG010","title":"Part PK Dose Level 2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Evaluable patients for response","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}